登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL
ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由上海交通大学医学院附属瑞金医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07380984,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
At least one measurable/evaluable disease site confirmed by diagnostic biopsy prior to the initiation of treatment.
入选标准第 6 条
Prior treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents.
排除标准第 11 条
Use of systemic immunosuppressive agents within 2 weeks prior to the initiation of study treatment, or planned use of such agents during the study period, including cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor (anti-TNF) drugs.
排除标准第 13 条
Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.
入选标准第 7 条
Absolute neutrophil count (ANC) > 1,000/μL
入选标准第 11 条
Platelet count > 50,000/μL
入选标准第 12 条
Hemoglobin > 9 g/dL
入选标准第 13 条
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3× upper limit of normal (ULN)
入选标准第 14 条
Serum total bilirubin < 1.5 × ULN (patients with Gilbert's syndrome are eligible)
入选标准第 15 条
Serum creatinine < 2 × ULN or creatinine clearance > 50 mL/min
入选标准第 16 条
A history of autoimmune disease requiring systemic treatment (i.e., with disease-modifying antirheumatic drugs, corticosteroids, or immunosuppressants) within the past 2 years, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody-associated vasculopathy, granulomatosis with polyangiitis (Wegener's), Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.
排除标准第 3 条
A history of other invasive malignancies within the past 3 years that has not been treated with curative intent or is currently receiving anticancer therapy (including hormonal therapy for breast or prostate cancer).
排除标准第 4 条
Positive results for HBsAg, HCV, or HIV; HBV seropositivity is permitted only if HBV DNA < 1000 IU/mL;
排除标准第 8 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07380984,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
The subject has histopathologically confirmed extranodal NK/T-cell lymphoma, nasal type (according to the 2022 WHO classification). No prior history of anti-lymphoma therapy. Age ≥ 18 years. Life expectancy > 3 months. Ann Arbor stage I-II. At least one measurable/evaluable disease site confirmed by diagnostic biopsy prior to the initiation of treatment. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2. Signed informed consent form (ICF). Willingness and ability to comply with the study protocol. Sufficient bone marrow, hepatic, and renal function, defined as: Absolute neutrophil count (ANC) > 1,000/μL Platelet count > 50,000/μL Hemoglobin > 9 g/dL Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3× upper limit of normal (ULN) Serum total bilirubin < 1.5 × ULN (patients with Gilbert's syndrome are eligible) Serum creatinine < 2 × ULN or creatinine clearance > 50 mL/min Availability of tumor tissue samples (preferably fresh tissue; archived tissue samples are acceptable). For women of childbearing potential, agreement to use adequate contraception to avoid pregnancy during the study treatment period. For male, agreement to remain abstinent or use a barrier method of contraception.排除标准:Exclusion Criteria:
Advanced-stage disease (Ann Arbor Stage III-IV). Nonnasal-type NKTCL. A history of autoimmune disease requiring systemic treatment (i.e., with disease-modifying antirheumatic drugs, corticosteroids, or immunosuppressants) within the past 2 years, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody-associated vasculopathy, granulomatosis with polyangiitis (Wegener's), Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. A history of other invasive malignancies within the past 3 years that has not been treated with curative intent or is currently receiving anticancer therapy (including hormonal therapy for breast or prostate cancer). A history of (non-infectious) pneumonia requiring corticosteroid therapy; or clinical evidence of interstitial lung disease or active, non-infectious pneumonia. Active infections requiring systemic treatment, including: A known history of active tuberculosis; Positive results for HBsAg, HCV, or HIV; HBV seropositivity is permitted only if HBV DNA < 1000 IU/mL; Active viral infections other than hepatitis B and C (e.g., herpes zoster). Severe cardiovascular disease, including myocardial infarction, unstable arrhythmia, or unstable angina occurring within the past 3 months. Prior treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents. Administration of live-attenuated vaccines within 4 weeks prior to the initiation of study treatment; patients are prohibited from receiving live-attenuated vaccines during the study period, including influenza vaccines. Use of systemic immunosuppressive agents within 2 weeks prior to the initiation of study treatment, or planned use of such agents during the study period, including cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor (anti-TNF) drugs. Evidence of central nervous system involvement. A history of allogeneic tissue/solid organ transplantation. A history of severe hypersensitivity reactions (Grade ≥ 3) to PD-1 monoclonal antibodies and/or their excipients, or to gorlitinib and/or its excipients. Any other factors judged by the investigator to potentially affect compliance with the study protocol.
引自 ClinicalTrials.gov, NCT07380984, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07380984,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。